Dr. Stavroula Otis

Hematology
1401 N Tustin Ave, Suite 220, 
Santa Ana, CA 
Offers Telehealth
1401 N Tustin Ave, Suite 220, 
Santa Ana, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stavroula Otis is a Hematologist in Santa Ana, California. Dr. Otis is rated as an Experienced provider by MediFind in the treatment of Anal Cancer. Her top areas of expertise are Follicular Lymphoma, Myelodysplastic Syndrome (MDS), Agranulocytosis, and Anemia.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in CA
Hospital Affiliations
Providence St. Joseph Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CENTER FOR CANCER AND BLOOD DISORDERS
1401 N Tustin Ave, Suite 220, Santa Ana, CA 92705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Unknown
Publish Date: October 15, 2021
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

1 Total Publications

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2013
Similar Doctors
Distinguished in Anal Cancer
Dr. Edwin L. Jacobs
Oncology | Hematology
Distinguished in Anal Cancer
Dr. Edwin L. Jacobs
Oncology | Hematology
181 South Buena Vista Street, Floor 4, 
Burbank, CA 
 (39.7 miles away)
818-840-0921
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edwin Jacobs is a Hematologist and an Oncologist in Burbank, California. Dr. Jacobs is rated as a Distinguished provider by MediFind in the treatment of Anal Cancer. His top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Anal Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Jacobs is currently accepting new patients.

Distinguished in Anal Cancer
Dr. Afsaneh Barzi
Oncology | Hematology
Distinguished in Anal Cancer
Dr. Afsaneh Barzi
Oncology | Hematology
1441 Eastlake Ave, Nor 8302e, 
Los Angeles, CA 
 (29.9 miles away)
323-865-3105
Languages Spoken:
English
See accepted insurances

Afsaneh Barzi is an Oncologist and a Hematologist in Los Angeles, California. Dr. Barzi is rated as an Elite provider by MediFind in the treatment of Anal Cancer. Her top areas of expertise are Colorectal Cancer, Stomach Cancer, Lynch Syndrome, Prostatectomy, and Endoscopy.

Distinguished in Anal Cancer
Dr. Derek A. Helton
Hematology Oncology | Hematology | Oncology
Distinguished in Anal Cancer
Dr. Derek A. Helton
Hematology Oncology | Hematology | Oncology

Regents Of The University Of California

910 Sycamore Ave, 
Vista, CA 
 (54.4 miles away)
858-657-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Derek Helton is a Hematologist Oncology specialist and a Hematologist in Vista, California. Dr. Helton is rated as a Distinguished provider by MediFind in the treatment of Anal Cancer. His top areas of expertise are Anal Cancer, Familial Colorectal Cancer, Stomach Cancer, and Pancreatic Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Otis's expertise for a condition
ConditionClose
      View All 36 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile